Matthew Germinaro
Allergy and Immunology
3737 Market Street
3rd Floor
Philadelphia, PA 19104
3rd Floor
Philadelphia, PA 19104
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Multiomic characterisation of the clinical efficacy of guselkumab induction therapy in ulcerative colitis.
Journal: BMJ open gastroenterology
Published: October 28, 2025
Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study.
Journal: The American journal of gastroenterology
Published: October 15, 2025
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial.
Journal: The lancet. Gastroenterology & hepatology
Published: June 30, 2025
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Journal: Lancet (London, England)
Published: July 12, 2024
Qualitative and Psychometric Evaluation of 29-Item Patient-Reported Outcomes Measurement Information System® to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel Disease.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 27, 2023
Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease.
Journal: Journal of patient-reported outcomes
Published: February 13, 2023
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions.
Journal: Journal of Crohn's & colitis
Published: November 21, 2022
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Journal: The lancet. Gastroenterology & hepatology
Published: October 13, 2022
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
Journal: Gastroenterology
Published: September 13, 2021
IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy.
Journal: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
Published: March 12, 2019
Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients with Severe Eosinophilic Asthma.
Journal: American journal of respiratory and critical care medicine
Published: October 23, 2018
Last Updated: 09/26/2026